Mavacamten Poised to Expand to Pediatric Obstructive Hypertrophic Cardiomyopathy

(MedPage Today) — NEW ORLEANS — The benefit of mavacamten (Camzyos) held up in symptomatic adolescents with obstructive hypertrophic cardiomyopathy (HCM), the phase III SCOUT-HCM trial showed.
Already available to adults, the cardiac myosin…